References
- Zhou P, Yang XL, Wang XG, Hu B, Zhang L, Zhang W, et al. A pneumonia
outbreak associated with a new coronavirus of probable bat origin.
Nature. 2020;579(7798):270–3.
- Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. A novel corona
virüs from patients with pneumonia in China, 2019. N Engl. J. Med.
2020;382(8):727–33.
- Zhang JJ, Dong X, Cao YY, Yuan YD, Yang YB, Yan YQ. Clinical
characteristics of 140 patients infected with SARS-CoV-2 in Wuhan,
China. Allergy. 2020.
- Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological
and clinical characteristics of 99 cases of 2019 novel corona virüs
pneumonia in Wuhan, China: a descriptive study. Lancet.
2020;395(10223):507–13.
- Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features
of patients infected with 2019 novel coronavirus in Wuhan. China.
Lancet. 2020;395(10223):497–506.
- Xiong Y, Liu Y, CaoL, Wang D, Guo M, Jiang A, et al. Transcriptomic
characteristics of bronchoalveolar lavage fluid and peripheral blood
mononuclear cells in COVID-19 patients. Emerg Microbes Infect.
2020;9(1):761–70.
- Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical
characteristics of 138 hospitalized patients with 2019 novel
coronavirus-infected pneumonia in Wuhan, China. JAMA.
2020;323(11):1061.
- Tang N, Li D, Wang X, Sun Z. Abnormal coagulation parameters are
associated with poorprognosis in patients with novel corona virüs
pneumonia. J. Thromb. Haemost. 2020;18(4):844–7.
- Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and
risk factors formortality of adult in patients with COVID-19 in Wuhan,
China: a retrospective cohort study. Lancet. 2020;395(10229):1054–62.
- Luo W, YuH,Guo Z, Li X, Sun Y, Li J, et al. Clinical pathology of
critical patient with novel corona virüs pneumonia (COVID-19).
Preprints. 2020.www.preprints.org.
- Ding Y, Wang H, Shen H, Li Z, Geng J, Han H et al. The clinical
pathology of severe acute respiratory syndrome (SARS): a report from
China. J. Pathol. 2003;200(3):282–9.
- Klok FA, Kruip M, van der Meer NJM, Arbous MS, Gommers D, Kant KM, et
al. Incidence of thrombotic complications in critically ill ICU
patients with COVID-19. Thromb. Res. 2020. doi.10.1016/j. thromres.
2020.04.013.
- Cui S, Chen S, Li X, Liu S, Wang F. Prevalence of venous
thromboembolism in patients with severe novel corona virüs pneumonia.
J.Thromb. Haemost. 2020
- Xiong M, LiangX, Wei YD. Changes in blood coagulation in patients with
severe corona virüs disease 2019 (COVID-19): a meta-analysis. British
Society for Haematology and John Wiley&Sons Ltd. 2020.
- Connors JM, Levy JH. COVID-19 and it simplications for thrombosis and
anticoagulation. Blood. 2020.
- Bikdeli B, Madhavan MV, Jimenez D, Chuich T, Dreyfus I, Driggin E et
al. COVID-19 and thromboticor thromboembolic disease: Implications for
prevention, anti thrombotic therapy, andfollow-up. J. Am. Coll.
Cardiol. 2020;(4):0735-1097(20)35008-7.
- Zhang L, Yan X, Fan Q, Liu H, Liu X, Liu Z, Zhang Z. D-dimer levels on
admission to predict in hospital mortality in patients with Covid-19.
J. Thromb. Haemost. 2020;18(6):1324-1329.
- Lippi G, Plebani M, Henry BM. Thrombocytopenia is associated with
severe corona virüs disease 2019 (COVID-19) infections: a
meta-analysis. Clin. Chim. Acta. 2020;506:145-148.
- Khurana D, Deoke SA. Thrombocytopenia in critically ill patients:
clinical and laboratorial behavior and its correlation with short-
term outcome during hospitalization. Indian J. Crit. Care Med.
2017;21(12):861–864.
- Yang X, Yang Q, Wang Y, Wu Y, Xu J, Yu Y, et al. Thrombocytopenia and
its association with mortality in patients with COVID-19. J Thromb
Haemost. 2020;18:1469–72.
- Yang Z, Shi J, He Z, et al. Predictors for imaging progression on
chest CT from corona virüs disease 2019 (COVID-19) patients. Aging.
2020;12:6037–6048.
- Ganji A, Farahani I, Khansarinejad B, et al. Increased expression of
CD(8) marker on T-cells in COVID-19 patients. Blood Cells Mol. Dis.
2020;83:102437.
- Tang N, Bai H, Chen X, et al. Anticoagulant treatment is associated
with decreased mortality in severe corona virus disease 2019 patients
with coagulopathy. J. Thromb. Haemost. 2020;18(5):1094–1099.
- Wakai A, Gleeson A, Winter D. Role of fibrin D-dimertesting in
emergency medicine. Emergency Medicine Journal. 2003; 20: 319-325.
- Hayakawa M, Maekawa K, Kushimoto S, et al. High D-dimer levels predict
a pooroutcome in patients with severe trauma, even with high
fibrinogen levels on arrival: a multi center retrospective
study. Shock 2016; 45(3): 308–314.
- Schutte T, Thijs A, Smulders YM. Never ignore extremely elevated
D-dimer levels: they are specific for serious illness. The Netherlands
Journal of Medicine 2016; 74(10): 443–448.
- Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, et al. Clinical
characteristics of corona virüs disease 2019 in China. N. Engl. J.
Med. 2020;382:1708–20.
- Petrilli CM, Jones SA, Yang J, Rajagopalan H, O’Donnel L, Chernyak Y,
et al. Factors associated with hospital admission and critical illness
among 5279 people with corona virüs disease 2019 in New York City:
prospective cohort study. BMJ. 2020;369: m1966.
- Guo T, Fan Y, Chen M, Wu X, Zhang L, He T, Wang H, Wan J, Wang X, Lu
Z. Cardiovascular implications of fatal outcomes of patients with
corona virüs disease 2019 (COVID-19). JAMA Cardiology. 2019.